Maria L. A. C. Bordon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maria L. A. C. Bordon has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Luiz Felipe Domingues Passero
Institute of Biosciences, São Paulo State University (UNESP), Praça Infante Dom Henrique, s/n, São Vicente 11330-900, Brazil
2 shared publications - Marcos Hikari Toyama
UNESP
2 shared publications - Márcia Dalastra Laurenti
Laboratory of Pathology of Infectious Diseases (LIM50), Department of Pathology, Medical School, São Paulo University, São Paulo 01246-903, Brazil
2 shared publications - Adriana Franco Paes Leme
Advanced Clusters in Health Technologies (NATS), Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy and Materials (CNPEM), Campinas, São Paulo, Brazil
1 shared publication - Alexis Bonfim-Melo
Frazer Institute, Faculty of Health, Medicine, and Behavioural Sciences, University of Queensland, Brisbane, Australia
1 shared publication - Ana Kely Carvalho
Depto. de Patologia da Faculdade de Medicina da Universidade de São Paulo, Laboratório de Patologia de Moléstias Infecciosas (LIM-50), São Paulo, Brazil
1 shared publication
Latest Publications
- Open Access
- 27 August 2018
- Published by Springer Nature in Journal of Venomous Animals and Toxins including Tropical Diseases
- Vol. 24 (1) , 21
Effect of phospholipase A2 inhibitors during infection caused by Leishmania (Leishmania) amazonensis
Lipid metabolites play an important role in parasite differentiation and virulence. Studies have revealed that Leishmania sp. uses prostaglandins to evade innate barriers, thus enabling the parasites to survive inside immune cells. Despite the role of the enzyme Phospholipase A2 (PLA2) in prostaglandins production, few studies have investigated the role of parasite PLA2 during the interaction between L. (L.) amazonensis and the host (in vitro and in vivo) immune cells. In the present work, the leishmanicidal effect of PLA2 inhibitors, methyl arachidonyl fluorophosphonate (MAFP), bromoenol lactone (BEL) and aristolochic acid (AA) were investigated in vitro (promastigote and intracellular amastigote forms of L. (L.) amazonensis) and during in vivo infection using BALB/c mice. The aforementioned inhibitors were deleterious to promastigote and amastigote forms of the L. (L.) amazonensis and were non-toxic to peritoneal macrophages from BALB/c mice. L. (L.) amazonensis-infected BALB/c mice treated with the inhibitor BEL presented decreased lesion size and skin parasitism; however, BEL treatment induced hepatotoxicity in BALB/c mice. Results presented herein suggested that PLA2 inhibitors altered L. (L.) amazonensis viability. In spite of liver toxicity, treatment with BEL was the most selective compound in vitro, as well in vivo, resulting in lower skin parasitism in the infected mice. These findings corroborate the role of PLA2 in parasite virulence and maintenance in vertebrate hosts, and suggest that molecules structurally related to BEL should be considered when planning compounds against Leishmania sp.
- 27 August 2018
- Published by Springer Nature in Journal of Venomous Animals and Toxins including Tropical Diseases
- Vol. 24 (1) , 21
Open AccessEffect of phospholipase A2 inhibitors during infection caused by Leishmania (Leishmania) amazonensis
Lipid metabolites play an important role in parasite differentiation and virulence. Studies have revealed that Leishmania sp. uses prostaglandins to evade innate barriers, thus enabling the parasites to survive inside immune cells. Despite the role of the enzyme Phospholipase A2 (PLA2) in prostaglandins production, few studies have investigated the role of parasite PLA2 during the interaction between L. (L.) amazonensis and the host (in vitro and in vivo) immune cells. In the present work, the leishmanicidal effect of PLA2 inhibitors, methyl arachidonyl fluorophosphonate (MAFP), bromoenol lactone (BEL) and aristolochic acid (AA) were investigated in vitro (promastigote and intracellular amastigote forms of L. (L.) amazonensis) and during in vivo infection using BALB/c mice. The aforementioned inhibitors were deleterious to promastigote and amastigote forms of the L. (L.) amazonensis and were non-toxic to peritoneal macrophages from BALB/c mice. L. (L.) amazonensis-infected BALB/c mice treated with the inhibitor BEL presented decreased lesion size and skin parasitism; however, BEL treatment induced hepatotoxicity in BALB/c mice. Results presented herein suggested that PLA2 inhibitors altered L. (L.) amazonensis viability. In spite of liver toxicity, treatment with BEL was the most selective compound in vitro, as well in vivo, resulting in lower skin parasitism in the infected mice. These findings corroborate the role of PLA2 in parasite virulence and maintenance in vertebrate hosts, and suggest that molecules structurally related to BEL should be considered when planning compounds against Leishmania sp.
- Open Access
- 30 March 2012
- Published by Springer Nature in Parasites & Vectors
- Vol. 5 (1) , 64
Proteins of Leishmania (Viannia) shawi confer protection associated with Th1 immune response and memory generation
Leishmania (Viannia) shawi parasite was first characterized in 1989. Recently the protective effects of soluble leishmanial antigen (SLA) from L. (V.) shawi promastigotes were demonstrated using BALB/c mice, the susceptibility model for this parasite. In order to identify protective fractions, SLA was fractionated by reverse phase HPLC and five antigenic fractions were obtained.
- 30 March 2012
- Published by Springer Nature in Parasites & Vectors
- Vol. 5 (1) , 64
Open AccessProteins of Leishmania (Viannia) shawi confer protection associated with Th1 immune response and memory generation
Leishmania (Viannia) shawi parasite was first characterized in 1989. Recently the protective effects of soluble leishmanial antigen (SLA) from L. (V.) shawi promastigotes were demonstrated using BALB/c mice, the susceptibility model for this parasite. In order to identify protective fractions, SLA was fractionated by reverse phase HPLC and five antigenic fractions were obtained.